Somatostatin Analog

This page covers all Somatostatin Analog drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Somatostatin receptor type 2, Somatostatin receptors (SSTR1, SSTR3, SSTR5), Somatostatin receptors (SSTR2, SSTR5).

Targets

Somatostatin receptor type 2 · Somatostatin receptors (SSTR1, SSTR3, SSTR5) · Somatostatin receptors (SSTR2, SSTR5) · Somatostatin receptor 2 (SSTR2) · Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor · Somatostatin receptor type 5 · Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide) · Somatostatin receptors (SSTR) · Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3 · Somatostatin receptor 2 (SSTR2); somatostatin receptors

Marketed (17)

• Somatuline Depot · Ipsen Pharma · Other · 1200
  Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone.
• Sandostatin · Novartis · Oncology · 305
  Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors.
• Signifor (pasireotide) · Zealand University Hospital · Endocrinology
  Pasireotide is a somatostatin receptor agonist that binds to multiple somatostatin receptor subtypes to suppress hormone secretion and inhibit tumor growth.
• Sandostatin LAR · Pfizer · Endocrinology / Oncology
  Sandostatin LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• Copper Cu 64 Dotatate · Vanderbilt-Ingram Cancer Center · Oncology
  Copper Cu 64 Dotatate is a radioactive imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing PET visualization and localization of these tumors.
• combination with somatostatin analogue octreotide · Ludwig-Maximilians - University of Munich · Oncology
  Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
• Octreotide LAR · Cedars-Sinai Medical Center · Endocrinology, Oncology
  Octreotide LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone, insulin, and other hormones.
• Sandostatin ® injection · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Oncology; Endocrinology
  Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones.
• Indium-111 pentetreotide · Radio Isotope Therapy of America · Oncology
  Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors.
• Octreotide (drug) · Lahore General Hospital · Oncology; Endocrinology
  Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.
• Somatostatin analog · The Netherlands Cancer Institute · Oncology
  Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth.
• norepinephrine versus midodrine & octreotide · National Hepatology & Tropical Medicine Research Institute · Gastroenterology / Hepatology
  Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications.
• LAR Lanreotide · Memorial Sloan Kettering Cancer Center · Oncology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• Signifor · Recordati · Oncology
  Signifor works by binding to somatostatin receptors on the surface of cells, mimicking the natural hormone somatostatin to reduce cortisol production.
• Inj. Octreotide · PVS Memorial Hospital · Oncology
  Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors.
• Pegvisomant/ Sandostatin LAR · Pfizer · Endocrinology
  Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion.
• Octreotide Injection · Centre Hospitalier Universitaire, Amiens · Oncology; Endocrinology
  Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce blood flow to tumors.

Phase 3 pipeline (16)

• Lanreotide microparticles · Ipsen · Oncology, Endocrinology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• 177Lu-edotreotide · Grupo Espanol de Tumores Neuroendocrinos · Oncology
  177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them.
• Aminopan · Other
  Aminopan works by binding to somatostatin receptors on cells, which blocks the release of hormones and growth factors.
• Lanreotide ATG · Camurus AB · Oncology / Endocrinology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• 177Lu-DOTA0-Tyr3-Octreotate · Advanced Accelerator Applications · Oncology
  177Lu-DOTA0-Tyr3-Octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.
• Somatostatin (octreotide) · University Hospital Freiburg · Oncology; Endocrinology
  Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.
• Long-acting somatostatin · Mario Negri Institute for Pharmacological Research · Endocrinology / Oncology
  Long-acting somatostatin is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
• long-acting Octreotide. · Jiangsu HengRui Medicine Co., Ltd. · Oncology; Endocrinology
  Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
• IPN10200 · Ipsen · Oncology
  IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth.
• Lanreotide LP 90 · University Hospital, Limoges · Oncology; Endocrinology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• Sanvar® (vapreotide) · Debiovision · Oncology
  Vapreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce symptoms in neuroendocrine tumors.
• Octreotide Microspheres · Shanghai Zhongshan Hospital · Oncology
  Octreotide microspheres are a long-acting formulation of the somatostatin analog octreotide that binds somatostatin receptors to inhibit hormone secretion and tumor growth.
• 68Ga-DOTATOC · Montefiore Medical Center · Oncology; Nuclear Medicine/Diagnostic Imaging
  68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging.
• octreotide capsules · Chiasma, Inc. · Endocrinology
  Octreotide capsules mimic the natural hormone somatostatin to decrease production of growth hormone and other hormones.
• [Lu-177]-PNT2002 · POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company · Oncology
  [Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy.
• Placebo lanreotide · University Hospital, Limoges · Endocrinology
  Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones.

Phase 2 pipeline (2)

• Lu-177 DOTA-TATE · AHS Cancer Control Alberta · Oncology
  Lu-177 DOTA-TATE is a radiolabeled peptide that targets somatostatin receptors on neuroendocrine tumors.
• 64Cu-DOTA-AE105 · Curasight · Oncology
  Somatostatin receptor targeting

Phase 1 pipeline (6)

• 131I-IPA · Telix Pharmaceuticals (Innovations) Pty Limited · Oncology
  Iodine-131 labelled peptide for targeted radionuclide therapy
• 177Lu-RAD204 · Radiopharm Theranostics, Ltd · Oncology
  Alpha-particle emitting radioligand targeting somatostatin receptors
• 177Lu-BetaBart · Radiopharm Theranostics, Ltd · Oncology
  Targeting somatostatin receptors
• 153Sm-DOTMP · Telix Pharmaceuticals (Innovations) Pty Limited · Oncology
  A radioligand targeting somatostatin receptors
• 64Cu-DOTA-TLX592 · Telix Pharmaceuticals (Innovations) Pty Limited · Oncology
  Somatostatin receptor targeting
• 177Lu-DOTA-EB-TATE · Molecular Targeting Technologies, Inc. · Oncology
  Somatostatin receptor targeting

Patent intelligence

• somatostatin patent landscape — aggregated cliff calendar, attackable patents, originator estates